HIV Prevention Clinical Trials Database

A comprehensive source of information on biomedical HIV prevention clinical trials

Our database allows users to view planned, ongoing, and completed clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.

Search or Filter



Results

showing 1-20 of 65

Trial Name

HPTN 096

Ongoing
Prevention Option
PrEP, Treatment U=U
Start Date
April 1, 2022
End Date
June 30, 2027
Population
Gay and Bisexual Men Who Have Sex with Men, People Living with HIV
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
DIAID, HPTN, NAID
Trial Name

HPTN 074

Completed
Prevention Option
PrEP, Treatment U=U
Start Date
February 1, 2015
End Date
June 30, 2018
Population
Injecting drug users, People Living with HIV
Country
Indonesia, Thailand, Ukraine
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
HPTN, NIAID, NIDA
Trial Name

HPTN 078

Completed
Prevention Option
Treatment U=U
Start Date
June 6, 2016
End Date
February 8, 2019
Population
Gay and Bisexual Men Who Have Sex with Men, People Living with HIV
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
NIAID (DAIDS ID: 11995)
Trial Name

MK-8527-004

Planned
Prevention Option
Treatment U=U
Start Date
September 20, 2022
End Date
September 20, 2022
Population
Cisgender Men, Cisgender Women
Product Candidate
MK-8527
Sponsors
Merck Sharp & Dohme LLC
Trial Name

HPTN 094/ INTEGRA

Ongoing
Prevention Option
PrEP, Treatment U=U
Start Date
June 9, 2021
End Date
Population
Cisgender Men, Cisgender Women, Injecting drug users, People Living with HIV
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
NIAID (DAIDS ID: 38715)
Trial Name

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Completed
Prevention Option
Treatment U=U
Start Date
November 26, 2018
End Date
June 15, 2020
Population
Cisgender Men
Country
United States of America
Product Candidate
Lenacapavir , JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Gilead
Trial Name

Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care

Ongoing
Prevention Option
Treatment U=U
Start Date
August 1, 2013
End Date
January 1, 2016
Population
Country
Haiti
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Trial Name

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (TasP)

Ongoing
Prevention Option
Treatment U=U
Start Date
December 20, 2011
End Date
December 20, 2016
Population
Cisgender Men, Cisgender Women
Country
South Africa
Product Candidate
TDF/FTC (Truvada)
Trial Name

Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC) (MP3)

Prevention Option
Treatment U=U
Start Date
March 1, 2013
End Date
March 1, 2018
Population
Gay and Bisexual Men Who Have Sex with Men
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Trial Name

Opposites Attract Study

Ongoing
Prevention Option
Treatment U=U
Start Date
January 31, 2011
End Date
December 31, 2015
Population
Gay and Bisexual Men Who Have Sex with Men
Country
Australia
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
National Health and Medical Research Council
Trial Name

HPTN 052

Completed
Prevention Option
Treatment U=U
Start Date
February 1, 2005
End Date
May 8, 2015
Population
Cisgender Men, Cisgender Women
Country
Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, United States of America, Zimbabwe
Product Candidate
Efavirenz, Stavudine, TDF/FTC (Truvada), Zidovudine/Lamivudine, Nevirapine
Sponsors
HPTN, NIAID
Trial Name

START

Completed
Prevention Option
Treatment U=U
Start Date
March 31, 2009
End Date
July 16, 2015
Population
Cisgender Men, Cisgender Women, People Living with HIV
Country
Argentina, Australia, Austria, Belgium, Brazil, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Luxembourg, Malaysia, Mali, Mexico, Morocco, Nigeria, Norway, Peru, Poland, Portugal, Puerto Rico, South Africa, Spain, Sweden, Switzerland, Thailand, Uganda, United Kingdom
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
University of Minnesota - Clinical and Translational Science Institute
Trial Name

Study to evaluate the feasibility of universal HIV testing and ART regardless of CD4 count using the Test and Treat strategy among MSM and transgender women

Ongoing
Prevention Option
Treatment U=U
Start Date
January 31, 2012
End Date
December 31, 2015
Population
Gay and Bisexual Men Who Have Sex with Men, People Living with HIV
Country
Thailand
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Department of Disease Control at the Ministry of Public Health, Government Pharmaceutical Organization, National Research Council, National Security Office, TREAT Asia, WHO and AIDS fund
Trial Name

Seek and treat for optimal prevention of HIV/AIDS in IDU

Completed
Prevention Option
Treatment U=U
Start Date
January 31, 2008
End Date
December 31, 2013
Population
Injecting drug users, People Living with HIV
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
British Columbia Ministry of Health, NIH
Trial Name

APTcare

Ongoing
Prevention Option
Treatment U=U
Start Date
March 19, 2014
End Date
March 19, 2014
Population
Cisgender Men, Cisgender Women, People Living with HIV
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
CDC
Trial Name

Periodic HIV testing and counselling and immediate ART among PWID

Planned
Prevention Option
Treatment U=U
Start Date
January 31, 2013
End Date
December 31, 2015
Population
Injecting drug users, People Living with HIV
Country
Vietnam
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Viet Nam Authority for HIV/AIDS Control - Ministry of Health and WHO
Trial Name

Enhanced access to HIV care for drug users

Ongoing
Prevention Option
Treatment U=U
Start Date
August 31, 2013
End Date
April 30, 2017
Population
Cisgender Men, Cisgender Women, Injecting drug users
Country
Puerto Rico
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
Columbia University
Trial Name

LINK LA

Prevention Option
Treatment U=U
Start Date
January 31, 2012
End Date
April 10, 2014
Population
Cisgender Men
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
NIH, UCLA
Trial Name

Behavioural intervention to enhance HIV test/treat

Ongoing
Prevention Option
Treatment U=U
Start Date
February 29, 2012
End Date
February 29, 2016
Population
Cisgender Men, Cisgender Women, People Living with HIV
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
University of Connecticut
Trial Name

Assessing the Impact of ART on Population Level Incidence of HIV/AIDS

Ongoing
Prevention Option
Treatment U=U
Start Date
January 31, 2011
End Date
December 31, 2015
Population
Cisgender Men, Cisgender Women, People Living with HIV
Country
Uganda
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI

showing 1-20 of 65